Tamilarasi Kannan, MD
Internal Medicine · Charlotte, NCNPI 1487628657
Payments from drug & device makers
Across 564 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$849
- Bayer$738
- Lilly USA, LLC$711
- Astellas Pharma US Inc$674
- AbbVie$520
- plus $4K from 31 others
What the payments were for
- Food & beverage$9,02199%
- Education$1071%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 139 | $1,838 |
| AstraZeneca | 39 | $849 |
| Bayer | 54 | $738 |
| Lilly USA, LLC | 43 | $711 |
| Astellas Pharma US Inc | 28 | $674 |
| AbbVie(2 entities) | 35 | $520 |
| Pfizer | 32 | $493 |
| GSK | 30 | $489 |
| Boehringer Ingelheim | 25 | $422 |
| Amgen | 21 | $333 |
| Exact Sciences | 15 | $307 |
| Sumitomo Pharma America, Inc. | 11 | $263 |
| Novartis | 13 | $202 |
| Idorsia Pharmaceuticals US Inc | 8 | $172 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $158 |
| Sanofi-aventis U.S. LLC | 7 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $118 |
| E.r. Squibb & Sons, L.L.C. | 5 | $87 |
| Amarin Pharma, Inc. | 6 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $60 |
| Merck | 4 | $59 |
| Eisai Inc. | 4 | $59 |
| Organon | 3 | $46 |
| Boston Scientific | 1 | $45 |
| Johnson & Johnson | 2 | $32 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Topcon Healthcare Solutions, Inc. | 1 | $31 |
| Exeltis, USA Inc. | 2 | $27 |
| Abbott | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Medtronic | 1 | $18 |
| Gilead | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$9,128 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 216 | $258,650 |
| MounjaroTirzepatide | 106 | $189,955 |
| OzempicSemaglutide | 112 | $137,299 |
| EliquisApixaban | 95 | $95,317 |
| JanuviaSitagliptin Phosphate | 60 | $80,507 |
| FarxigaDapagliflozin Propanediol | 67 | $78,662 |
| RybelsusSemaglutide | 42 | $70,392 |
| LinzessLinaclotide | 72 | $68,259 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $47,248 |
| EntrestoSacubitril/Valsartan | 20 | $26,649 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $21,407 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $18,007 |
| XareltoRivaroxaban | 18 | $15,970 |
| MyrbetriqMirabegron | 22 | $13,443 |
| Spiriva HandihalerTiotropium Bromide | 12 | $11,891 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $422 | $258,650216 claims |
| Novo NordiskOzempic, Rybelsus | $1,838 | $207,691154 claims |
| Lilly USA, LLCMounjaro | $711 | $189,955106 claims |
| PfizerEliquis | $493 | $95,31795 claims |
| MerckJanuvia | $59 | $80,50760 claims |
| AstraZenecaFarxiga | $849 | $78,66267 claims |
| AbbVieLinzess | $520 | $68,25972 claims |
| GSKTrelegy Ellipta | $489 | $47,24853 claims |
| NovartisEntresto | $202 | $26,64920 claims |
| Johnson & JohnsonXarelto, Invokana | $32 | $22,07930 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $125 | $18,00717 claims |
| Astellas Pharma US IncMyrbetriq | $674 | $13,44322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Charlotte
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- Lyndsay MolinariCharlotte$2.4M
- Claud GriggCharlotte$1.5M
- Maher AghaCharlotte$1M
- Jonathan SchwartzCharlotte$824K
- Marc JohnsonCharlotte$823K
- Santosh GopalakrishnanCharlotte$598K
- Maithili ChitnavisCharlotte$536K
- Christopher FerreriCharlotte$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.